These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
338 related items for PubMed ID: 12491500
1. Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma. Diamanti-Kandarakis E, Sykiotis GP, Papavassiliou AG. Cancer; 2003 Jan 01; 97(1):12-20. PubMed ID: 12491500 [Abstract] [Full Text] [Related]
2. [An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)]. Tinelli A, Perrone A, Tinelli FG. Minerva Ginecol; 2001 Apr 01; 53(2):127-35. PubMed ID: 11319506 [Abstract] [Full Text] [Related]
3. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Cancer; 2004 Oct 01; 101(7):1490-500. PubMed ID: 15378477 [Abstract] [Full Text] [Related]
4. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Lewis JS, Jordan VC. Mutat Res; 2005 Dec 11; 591(1-2):247-63. PubMed ID: 16083919 [Abstract] [Full Text] [Related]
5. Selective estrogen receptor modulators and postmenopausal health. Roe EB, Chiu KM, Arnaud CD. Adv Intern Med; 2000 Dec 11; 45():259-78. PubMed ID: 10635051 [Abstract] [Full Text] [Related]
6. Selective estrogen receptor modulators: an update on recent clinical findings. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Obstet Gynecol Surv; 2008 Mar 11; 63(3):163-81. PubMed ID: 18279543 [Abstract] [Full Text] [Related]
11. [Menopause and hormone replacement therapy]. Tóth KS. Orv Hetil; 2000 Mar 12; 141(11):547-56. PubMed ID: 10741167 [Abstract] [Full Text] [Related]
12. Postmenopausal hormone replacement therapy: endometrial and breast effects. Yeh IT. Adv Anat Pathol; 2007 Jan 12; 14(1):17-24. PubMed ID: 17198307 [Abstract] [Full Text] [Related]
13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Lee WL, Chao HT, Cheng MH, Wang PH. Maturitas; 2008 Jun 20; 60(2):92-107. PubMed ID: 18534794 [Abstract] [Full Text] [Related]
14. SERMs: progress and future perspectives. Pickar JH, MacNeil T, Ohleth K. Maturitas; 2010 Oct 20; 67(2):129-38. PubMed ID: 20580502 [Abstract] [Full Text] [Related]
15. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease]. Kozakiewicz K, Wycisk A. Wiad Lek; 2006 Oct 20; 59(5-6):377-82. PubMed ID: 17017486 [Abstract] [Full Text] [Related]
17. [Which is the better choice, estrogen or SERMs in postmenopausal women?]. Shintani M. Clin Calcium; 2004 Oct 20; 14(10):105-10. PubMed ID: 15577140 [Abstract] [Full Text] [Related]
18. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. Maeda T, Ke HZ, Simmons H, Thompson D. Clin Calcium; 2004 Oct 20; 14(10):85-93. PubMed ID: 15577137 [Abstract] [Full Text] [Related]
19. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient]. Kastelan D, Korsić M. Reumatizam; 2005 Oct 20; 52(2):67-70. PubMed ID: 16689133 [Abstract] [Full Text] [Related]